Connect with us

More headlines

CBD and genetic material could join forces to beat COVID-19

An Israeli study is investigating whether genetic material and a cannabis compound could work together as a potential treatment for COVID-19.



The collaborative project aims to develop a “novel, revolutionary” approach to treat COVID-19 by using the non-psychoactive compound CBD.

Specifically it hopes to treat the virus using CBD-loaded exomes – small particles created when stem cells are multiplied.

Exosomes can act as “homing missiles”, targeting specific damaged organs and have an important role in cell-to-cell communication.

Revolutionary exosome-based technology has the potential to target both central nervous system (CNS) problems and the COVID-19 virus.

CBD-loaded exosomes could provide a “highly synergistic” effect of anti-inflammatory properties and help in the recovery of infected lung cells.

A new product based on this technology, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The study is backed by Israeli firm InnoCan Pharma Ltd, which has entered a sponsored research agreement with Ramot, the technology transfer arm of Tel Aviv University.

They hope to develop a cell therapy product based on Professor Daniel Offen’s ongoing work in the field, with InnoCan contributing around US$450,000 to the first stage of the study.

The research results could lead to the development of and manufacture of a product to treat COVID-19 and, potentially, other types of lung inflammations and additional respiratory related illnesses.


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.